# A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.

> **NCT01160198** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 271 (actual)

## Conditions studied

- Haematopoiesis

## Interventions

- **DRUG:** ferrous ascorbate
- **DIETARY_SUPPLEMENT:** ferrous bisglycinate chelate 1 OD
- **DIETARY_SUPPLEMENT:** ferrous bisglycinate chelate 2 OD

## Key facts

- **NCT ID:** NCT01160198
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-13
- **Primary completion:** 2011-02-18
- **Final completion:** 2011-02-18
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2018-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160198, "A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01160198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*